Correlation Between Syndax Pharmaceuticals and Sutro Biopharma
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Sutro Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Sutro Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Sutro Biopharma, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Sutro Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Sutro Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Sutro Biopharma.
Diversification Opportunities for Syndax Pharmaceuticals and Sutro Biopharma
0.95 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between Syndax and Sutro is 0.95. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Sutro Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sutro Biopharma and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Sutro Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sutro Biopharma has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Sutro Biopharma go up and down completely randomly.
Pair Corralation between Syndax Pharmaceuticals and Sutro Biopharma
Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to under-perform the Sutro Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Syndax Pharmaceuticals is 1.49 times less risky than Sutro Biopharma. The stock trades about -0.09 of its potential returns per unit of risk. The Sutro Biopharma is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest 305.00 in Sutro Biopharma on September 29, 2024 and sell it today you would lose (116.00) from holding Sutro Biopharma or give up 38.03% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Strong |
Accuracy | 100.0% |
Values | Daily Returns |
Syndax Pharmaceuticals vs. Sutro Biopharma
Performance |
Timeline |
Syndax Pharmaceuticals |
Sutro Biopharma |
Syndax Pharmaceuticals and Sutro Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Syndax Pharmaceuticals and Sutro Biopharma
The main advantage of trading using opposite Syndax Pharmaceuticals and Sutro Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Sutro Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will offset losses from the drop in Sutro Biopharma's long position.Syndax Pharmaceuticals vs. Cogent Biosciences | Syndax Pharmaceuticals vs. Cullinan Oncology LLC | Syndax Pharmaceuticals vs. Kalvista Pharmaceuticals | Syndax Pharmaceuticals vs. Mersana Therapeutics |
Sutro Biopharma vs. Vaxcyte | Sutro Biopharma vs. Larimar Therapeutics | Sutro Biopharma vs. Syndax Pharmaceuticals | Sutro Biopharma vs. Merus BV |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |